Intertwined regulation of angiogenesis and immunity by myeloid cells

Trends in Immunology

Volumn 36, Issue 4, 2015, Pages 240-249

  Rivera, Lee B ^a,b   Bergers, Gabriele ^a,b,c  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

VASCULOTROPIN;

ANGIOGENESIS; ANTIANGIOGENIC THERAPY; BONE MARROW CELL; CELL HYPOXIA; CELL POPULATION; HELPER CELL; HUMAN; IMMUNITY; IMMUNOCOMPETENT CELL; IMMUNOSUPPRESSIVE TREATMENT; NEOVASCULARIZATION (PATHOLOGY); NONHUMAN; REVIEW; TUMOR MICROENVIRONMENT; IMMUNOLOGY; NEOPLASMS; PATHOLOGY; VASCULARIZATION;

HUMANS; IMMUNITY; MYELOID CELLS; NEOPLASMS; NEOVASCULARIZATION, PATHOLOGIC;

EID: 84926516814     PISSN: 14714906     EISSN: 14714981     Source Type: Journal    
DOI: 10.1016/j.it.2015.02.005     Document Type: Review

References (104)

1. Motz G.T., Coukos G. Deciphering and reversing tumor immune suppression. Immunity 2013, 39:61-73.
2. Bergers G., Benjamin L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. Cancer 2003, 3:401-410.
3. Baluk P., et al. Cellular abnormalities of blood vessels as targets in cancer. Curr. Opin. Genet. Dev. 2005, 15:102-111.
4. Carmeliet P. Angiogenesis in life, disease and medicine. Nature 2005, 438:932-936.
5. Dvorak H.F. Tumors: wounds that do not heal. Similarities between tumor stroma generation and wound healing. N. Engl. J. Med. 1986, 315:1650-1659.
6. Chi A.S., et al. Angiogenesis as a therapeutic target in malignant gliomas. Oncologist 2009, 14:621-636.
7. Gerstner E.R., et al. VEGF inhibitors in the treatment of cerebral edema in patients with brain cancer. Nat. Rev. Clin. Oncol. 2009, 6:229-236.
8. Hanahan D., Weinberg R.A. The hallmarks of cancer. Cell 2000, 100:57-70.
9. Jain R.K., et al. Biomarkers of response and resistance to antiangiogenic therapy. Nat. Rev. Clin. Oncol. 2009, 6:327-338.
10. Jain R.K. Antiangiogenic therapy for cancer: current and emerging concepts. Oncology 2005, 19:7-16.
11. Ebos J.M., Kerbel R.S. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat. Rev. Clin. Oncol. 2011, 8:210-221.
12. Lin E.Y., et al. Macrophages regulate the angiogenic switch in a mouse model of breast cancer. Cancer Res. 2006, 66:11238-11246.
13. Lin E.Y., et al. Vascular endothelial growth factor restores delayed tumor progression in tumors depleted of macrophages. Mol. Oncol. 2007, 1:288-302.
14. Giraudo E., et al. An amino-bisphosphonate targets MMP-9-expressing macrophages and angiogenesis to impair cervical carcinogenesis. J. Clin. Invest. 2004, 114:623-633.
15. Bergers G., et al. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell Biol. 2000, 2:737-744.
16. Du R., et al. HIF1alpha induces the recruitment of bone marrow-derived vascular modulatory cells to regulate tumor angiogenesis and invasion. Cancer Cell 2008, 13:206-220.
17. + cells in tumor-bearing host directly promotes tumor angiogenesis. Cancer Cell 2004, 6:409-421.
18. Pan P.Y., et al. Reversion of immune tolerance in advanced malignancy: modulation of myeloid-derived suppressor cell development by blockade of stem-cell factor function. Blood 2008, 111:219-228.
19. Schmid M.C., et al. Receptor tyrosine kinases and TLR/IL1Rs unexpectedly activate myeloid cell PI3Kgamma, a single convergent point promoting tumor inflammation and progression. Cancer Cell 2011, 19:715-727.
20. Kujawski M., et al. Stat3 mediates myeloid cell-dependent tumor angiogenesis in mice. J. Clin. Invest. 2008, 118:3367-3377.
21. Rigamonti N., et al. Role of angiopoietin-2 in adaptive tumor resistance to VEGF signaling blockade. Cell Rep. 2014, 8:696-706.
22. + myeloid cells. Nat. Biotechnol. 2007, 25:911-920.
23. Rolny C., et al. HRG inhibits tumor growth and metastasis by inducing macrophage polarization and vessel normalization through downregulation of PlGF. Cancer Cell 2011, 19:31-44.
24. Noy R., Pollard J.W. Tumor-associated macrophages: from mechanisms to therapy. Immunity 2014, 41:49-61.
25. Kumar V., Gabrilovich D.I. Hypoxia-inducible factors in regulation of immune responses in tumour microenvironment. Immunology 2014, 143:512-519.
26. Hanahan D., Weinberg R.A. Hallmarks of cancer: the next generation. Cell 2011, 144:646-674.
27. Kalluri R. Basement membranes: structure, assembly and role in tumour angiogenesis. Nat. Rev. Cancer 2003, 3:422-433.
28. Ferrara N. The role of VEGF in the regulation of physiological and pathological angiogenesis. Exs 2005, 2005:209-231.
29. Potente M., et al. Basic and therapeutic aspects of angiogenesis. Cell 2011, 146:873-887.
30. Jain R.K. Angiogenesis and lymphangiogenesis in tumors: insights from intravital microscopy. Cold Spring Harb. Symp. Quant. Biol. 2002, 67:239-248.
31. Senger D.R., et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219:983-985.
32. Junttila M.R., de Sauvage F.J. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature 2013, 501:346-354.
33. Oyama T., et al. Vascular endothelial growth factor affects dendritic cell maturation through the inhibition of nuclear factor-kappa B activation in hemopoietic progenitor cells. J. Immunol. 1998, 160:1224-1232.
34. Pardoll D.M. The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 2012, 12:252-264.
35. Motz G.T., Coukos G. The parallel lives of angiogenesis and immunosuppression: cancer and other tales. Nat. Rev. Immunol. 2011, 11:702-711.
36. Terme M., et al. Modulation of immunity by antiangiogenic molecules in cancer. Clin. Dev. Immunol. 2012, 2012:492920.
37. Ziogas A.C., et al. VEGF directly suppresses activation of T cells from ovarian cancer patients and healthy individuals via VEGF receptor type 2. Int. J. Cancer 2012, 130:857-864.
38. Coussens L.M., et al. MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis. Cell 2000, 103:481-490.
39. Bingle L., et al. Macrophages promote angiogenesis in human breast tumour spheroids in vivo. Br. J. Cancer 2006, 94:101-107.
40. Shojaei F., et al. Bv8 regulates myeloid-cell-dependent tumour angiogenesis. Nature 2007, 450:825-831.
41. Murdoch C., et al. The role of myeloid cells in the promotion of tumour angiogenesis. Nat. Rev. Cancer 2008, 8:618-631.
42. de Palma M., Coussens L.M. Immune cells and inflammatory mediators as regulators of tumor angiogenesis. Angiogenesis: An Integrative Approach from Science to Medicine 2008, Springer Science + Business Media. W.D. Figg, J. Folkman (Eds.).
43. Betsholtz C. Insight into the physiological functions of PDGF through genetic studies in mice. Cytokine Growth Factor Rev. 2004, 15:215-228.
44. Joyce J.A., et al. Cathepsin cysteine proteases are effectors of invasive growth and angiogenesis during multistage tumorigenesis. Cancer Cell 2004, 5:443-453.
45. Ferrara N., et al. The biology of VEGF and its receptors. Nat. Med. 2003, 9:669-676.
46. Compagni A., et al. Fibroblast growth factors are required for efficient tumor angiogenesis. Cancer Res. 2000, 60:7163-7169.
47. De Falco E., et al. SDF-1 involvement in endothelial phenotype and ischemia-induced recruitment of bone marrow progenitor cells. Blood 2004, 104:3472-3482.
48. Wang L., et al. Neuropilin-1-mediated vascular permeability factor/vascular endothelial growth factor-dependent endothelial cell migration. J. Biol. Chem. 2003, 278:48848-48860.
49. Du R., et al. Matrix metalloproteinase-2 regulates vascular patterning and growth affecting tumor cell survival and invasion in GBM. Neuro Oncol. 2008, 10:254-264.
50. Mantovani A., et al. Cancer-related inflammation. Nature 2008, 454:436-444.
51. Murray P.J., et al. Macrophage activation and polarization: nomenclature and experimental guidelines. Immunity 2014, 41:14-20.
52. Davies L.C., et al. Tissue-resident macrophages. Nat. Immunol. 2013, 14:986-995.
53. Pyonteck S.M., et al. CSF-1R inhibition alters macrophage polarization and blocks glioma progression. Nat. Med. 2013, 19:1264-1272.
54. Mitchem J.B., et al. Targeting tumor-infiltrating macrophages decreases tumor-initiating cells, relieves immunosuppression, and improves chemotherapeutic responses. Cancer Res. 2013, 73:1128-1141.
55. Strachan D.C., et al. CSF1R inhibition delays cervical and mammary tumor growth in murine models by attenuating the turnover of tumor-associated macrophages and enhancing infiltration by CD8 T cells. Oncoimmunology 2013, 2:e26968.
56. DeNardo D.G., et al. Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy. Cancer Discov. 2011, 1:54-67.
57. Affara N.I., et al. B cells regulate macrophage phenotype and response to chemotherapy in squamous carcinomas. Cancer Cell 2014, 25:809-821.
58. De Palma M., et al. Tie2-expressing monocytes: regulation of tumor angiogenesis and therapeutic implications. Trends Immunol. 2007, 28:519-524.
59. Pucci F., et al. A distinguishing gene signature shared by tumor-infiltrating Tie2-expressing monocytes, blood 'resident' monocytes, and embryonic macrophages suggests common functions and developmental relationships. Blood 2009, 114:901-914.
60. Jeltsch M., et al. Receptor tyrosine kinase-mediated angiogenesis. Cold Spring Harb. Perspect. Biol. 2013, 5:a009183.
61. Coffelt S.B., et al. Angiopoietin 2 stimulates TIE2-expressing monocytes to suppress T cell activation and to promote regulatory T cell expansion. J. Immunol. 2011, 186:4183-4190.
62. De Palma M., et al. Tie2 identifies a hematopoietic lineage of proangiogenic monocytes required for tumor vessel formation and a mesenchymal population of pericyte progenitors. Cancer Cell 2005, 8:211-226.
63. Mazzieri R., et al. Targeting the ANG2/TIE2 axis inhibits tumor growth and metastasis by impairing angiogenesis and disabling rebounds of proangiogenic myeloid cells. Cancer Cell 2011, 19:512-526.
64. Gerald D., et al. Angiopoietin-2: an attractive target for improved antiangiogenic tumor therapy. Cancer Res. 2013, 73:1649-1657.
65. Forget M.A., et al. Macrophage colony-stimulating factor augments Tie2-expressing monocyte differentiation, angiogenic function, and recruitment in a mouse model of breast cancer. PLoS ONE 2014, 9:e98623.
66. Chung A.S., et al. Targeting the tumour vasculature: insights from physiological angiogenesis. Nat. Rev. Cancer 2010, 10:505-514.
67. Fridlender Z.G., et al. Polarization of tumor-associated neutrophil phenotype by TGF-beta: 'N1' versus 'N2' TAN. Cancer Cell 2009, 16:183-194.
68. Talmadge J.E., Gabrilovich D.I. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 2013, 13:739-752.
69. + myeloid cells that promote metastasis. Cancer Cell 2008, 13:23-35.
70. Pahler J.C., et al. Plasticity in tumor-promoting inflammation: impairment of macrophage recruitment evokes a compensatory neutrophil response. Neoplasia 2008, 10:329-340.
71. Liao D., Johnson R.S. Hypoxia: a key regulator of angiogenesis in cancer. Cancer Metastasis Rev. 2007, 26:281-290.
72. Keith B., et al. HIF1alpha and HIF2alpha: sibling rivalry in hypoxic tumour growth and progression. Nat. Rev. Cancer 2011, 12:9-22.
73. Simon M.P., et al. The angiopoietin-2 gene of endothelial cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central factors GATA-2 and Ets-1. J. Cell. Physiol. 2008, 217:809-818.
74. Forsythe J.A., et al. Activation of vascular endothelial growth factor gene transcription by hypoxia-inducible factor 1. Mol. Cell. Biol. 1996, 16:4604-4613.
75. Kelly B.D., et al. Cell type-specific regulation of angiogenic growth factor gene expression and induction of angiogenesis in nonischemic tissue by a constitutively active form of hypoxia-inducible factor 1. Circ. Res. 2003, 93:1074-1081.
76. Murdoch C., et al. Mechanisms regulating the recruitment of macrophages into hypoxic areas of tumors and other ischemic tissues. Blood 2004, 104:2224-2234.
77. Avraham-Davidi I., et al. On-site education of VEGF-recruited monocytes improves their performance as angiogenic and arteriogenic accessory cells. J. Exp. Med. 2013, 210:2611-2625.
78. Grunewald M., et al. VEGF-induced adult neovascularization: recruitment, retention, and role of accessory cells. Cell 2006, 124:175-189.
79. Wang X., et al. Hypoxia enhances CXCR4 expression favoring microglia migration via HIF-1alpha activation. Biochem. Biophys. Res. Commun. 2008, 371:283-288.
80. Ishikawa T., et al. Hypoxia enhances CXCR4 expression by activating HIF-1 in oral squamous cell carcinoma. Oncol. Rep. 2009, 21:707-712.
81. Blouw B., et al. The hypoxic response of tumors is dependent on their microenvironment. Cancer Cell 2003, 4:133-146.
82. Casazza A., et al. Impeding macrophage entry into hypoxic tumor areas by Sema3A/Nrp1 signaling blockade inhibits angiogenesis and restores antitumor immunity. Cancer Cell 2013, 24:695-709.
83. Clambey E.T., et al. Hypoxia-inducible factor-1 alpha-dependent induction of FoxP3 drives regulatory T-cell abundance and function during inflammatory hypoxia of the mucosa. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:E2784-E2793.
84. Chung A.S., et al. An interleukin-17-mediated paracrine network promotes tumor resistance to anti-angiogenic therapy. Nat. Med. 2013, 19:1114-1123.
85. Welford A.F., et al. TIE2-expressing macrophages limit the therapeutic efficacy of the vascular-disrupting agent combretastatin A4 phosphate in mice. J. Clin. Invest. 2011, 121:1969-1973.
86. Fischer C., et al. Anti-PlGF inhibits growth of VEGF(R)-inhibitor-resistant tumors without affecting healthy vessels. Cell 2007, 131:463-475.
87. Gonzalez-Garcia A., et al. Phosphatidylinositol 3-kinase gamma inhibition ameliorates inflammation and tumor growth in a model of colitis-associated cancer. Gastroenterology 2010, 138:1374-1383.
88. Hirsch E., et al. Central role for G protein-coupled phosphoinositide 3-kinase gamma in inflammation. Science 2000, 287:1049-1053.
89. Chen W., et al. Macrophage-induced tumor angiogenesis is regulated by the TSC2-mTOR pathway. Cancer Res. 2012, 72:1363-1372.
90. Huang Y., et al. Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment and enhance immunotherapy. Proc. Natl. Acad. Sci. U.S.A. 2012, 109:17561-17566.
91. Hamzah J., et al. Vascular normalization in Rgs5-deficient tumours promotes immune destruction. Nature 2008, 453:410-414.
92. Schoenfeld J.D., Dranoff G. Anti-angiogenesis immunotherapy. Hum. Vaccin. 2011, 7:976-981.
93. Garber K. Promising early results for immunotherapy-antiangiogenesis combination. J. Natl. Cancer Inst. 2014, 106:dju392.
94. Hanahan D., Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 1996, 86:353-364.
95. De Bock K., et al. Role of PFKFB3-driven glycolysis in vessel sprouting. Cell 2013, 154:651-663.
96. Sawada N., et al. Endothelial PGC-1alpha mediates vascular dysfunction in diabetes. Cell Metab. 2014, 19:246-258.
97. Lyden D., et al. Impaired recruitment of bone-marrow-derived endothelial and hematopoietic precursor cells blocks tumor angiogenesis and growth. Nat. Med. 2001, 7:1194-1201.
98. + perivascular progenitor cells in tumours regulate pericyte differentiation and vascular survival. Nat. Cell Biol. 2005, 7:870-879.
99. Hlushchuk R., et al. Tumor recovery by angiogenic switch from sprouting to intussusceptive angiogenesis after treatment with PTK787/ZK222584 or ionizing radiation. Am. J. Pathol. 2008, 173:1173-1185.
100. Rubenstein J.L., et al. Anti-VEGF antibody treatment of glioblastoma prolongs survival but results in increased vascular cooption. Neoplasia 2000, 2:306-314.
101. Paez-Ribes M., et al. Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell 2009, 15:220-231.
102. Lu K.V., et al. VEGF inhibits tumor cell invasion and mesenchymal transition through a MET/VEGFR2 complex. Cancer Cell 2012, 22:21-35.
103. Sennino B., et al. Suppression of tumor invasion and metastasis by concurrent inhibition of c-Met and VEGF signaling in pancreatic neuroendocrine tumors. Cancer Discov. 2012, 2:270-287.
104. Bergers G., et al. Benefits of targeting both pericytes and endothelial cells in the tumor vasculature with kinase inhibitors. J. Clin. Invest. 2003, 111:1287-1295.